检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:戚东卫[1] 史丙俊[1] 唐雪勇 龚娟[1] QI Dong-wei;SHI Bing-jun;TANG Xue-yong;GONG Juan(Chongqing Hospital of Traditional Chinese Medicine,Department of Dermatology,Chongqing 400011,China)
出 处:《中药与临床》2022年第3期58-60,85,共4页Pharmacy and Clinics of Chinese Materia Medica
基 金:重庆市科卫联合中医药科研项目(ZY201802142);国家自然科学基金项目(81704091)
摘 要:目的:基于网络药理学,探讨甘芩治疗特应性皮炎(Atopic dermatitis,AD)的作用机制。方法:通过TCMSP数据库获取甘芩各药物的已知成分及其作用靶点,通过TCMSP和OMIM数据库获取AD的治疗靶点,进行交联分析,获得甘芩治疗AD的有效成分及作用靶点。用cytoscape软件构建甘芩中化合物与其靶点的网络,采用Davidv平台对作用靶点网络进行通路富集。结果:预测得到甘芩治疗AD的有效成分共158个和作用靶点60个。并推断其作用机制可能与PI3K-Akt信号通路、TNF信号通路、IL-17信号通路等有关,且IL-6、EGFR、ESR1、RELA、NFKBIA、IL-13等靶点基因可能起着主要作用。结论:基于网络药理学探讨了甘芩治疗AD多成分—多靶点—多通路的作用特点,为进一步开展甘芩开发研究提供了思路和方法。Objective:To probe into the mechanism of Ganqin in the treatment of atopic dermatitis(AD)based on network pharmacology.Method:The known components and targets of each drug in Ganqin were obtained through TCMSP database,and the treatment targets for AD were obtained through TCMSP and OMIM databases.Cross-linking analysis was performed to obtain the active components and targets of Ganqin Decoction in the treatment of AD.The network of the compounds and their targets in Ganqin was established through Cytoscape software,and the Davidv platform was used to perform pathway enrichment of the target network.Result:A total of 158 effective components and 60 targets of Ganqin in the treatment of AD were predicted.Its mechanism might be related to the PI3K-Akt,TNF and IL-17 signaling pathways,and the target genes such as IL-6,EGFR,ESR1,RELA,NFKBIA and IL-13,may played a crucial role.Conclusion:This study investigates the characteristics of multi-component,multi-target and multipathway of Ganqin in the treatment of AD,which provides ideas and methods for further development and research of Ganqin.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.28